Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHMSA Mozobil Coverage Policy Prior Auth | OpenPaye…
    Ask Trek AI about this page
    CurrentHawaii Medical Service Association (HMSA)Policy 03-2026

    Mozobil (plerixafor) Coverage

    Customize your policy alerts

    Sign up for Hawaii Medical Service Association (HMSA) Policy 03-2026 alerts

    Get alerted when Policy 03-2026 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs HMSA coverage and prior authorization for plerixafor used to mobilize hematopoietic stem cells for collection and subsequent transplantation or gene therapy protocols. It applies to members in the HMO, PPO, and QUEST lines of business when the coverage criteria and applicable benefit requirements are met.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyMozobil (plerixafor) Coverage
    Policy CodePolicy 03-2026
    Change TypeNo material change
    Effective DateJun 26, 2026
    Last ReviewMar 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for Mozobil (plerixafor) using the HMSA medical specialty drug policy fax form.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsMaximum authorization duration
    4 daysMaximum use duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3
    Permitted administration scenarios
    2Listed compendial uses

    Coverage Criteria

    Hematopoietic Stem Cell Mobilization

    Authorization of 6 months may be granted when both criteria are met.

    Hematopoietic stem cell mobilization

    • Permitted administration scenario

      • After G-CSF: The member has received a G-CSF, such as filgrastim.
      • After chemo-mobilization: The member has received chemo-mobilization.
      • Gene therapy protocol: The requested medication will be administered as part of a gene therapy protocol.
    • Duration limitation: The requested medication will not be used beyond 4 consecutive days or after completion of stem cell harvest/apheresis.4 consecutive days maximum and no use after completion of harvest/apheresis

    Continuation of Therapy

    All members, including new members and members currently receiving treatment without prior authorization, must meet all requirements for hematopoietic stem cell mobilization.

    Continuation therapy requirements

    • Permitted administration scenario

      • After G-CSF: The member has received a G-CSF, such as filgrastim.
      • After chemo-mobilization: The member has received chemo-mobilization.
      • Gene therapy protocol: The requested medication is being used as part of a gene therapy protocol.
    • Duration limitation:

    Treatment Limits

    Maximum Treatment Duration
    Maximum durationNo more than 4 consecutive days
    Post-harvest useTreatment must not continue after completion of stem cell harvest/apheresis
    Applies toThe requested medication used for hematopoietic stem cell mobilization

    Provider Requirements and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Mozobil (plerixafor). Submit the request using the fax form available on the HMSA medical specialty drug policy website.

    Step Therapy

    A-Rated Generic Trial Required Before Brand

    Before a brand medication can be approved, the member must try and fail an A-rated generic equivalent. Brand access requires failure due to an intolerable adverse event that is not an expected adverse event attributable to the active ingredient.

    • The generic trial must result in an intolerable adverse event, such as rash, nausea, or vomiting.
    • Differences in FDA-labeled indications between brand and generic products are not, by themselves, sufficient to permit brand access because the products contain identical active ingredients and have proven bioequivalent pharmacokinetics.

    Clinical Background

    Mozobil (plerixafor) is used with filgrastim to mobilize hematopoietic stem cells into the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin lymphoma or multiple myeloma. The policy also recognizes use for hematopoietic cell transplantation and as part of a gene therapy protocol.

    Key Definition

    Hematopoietic Stem Cell Mobilization
    ProcessMobilization of hematopoietic stem cells to the peripheral blood
    CollectionThe mobilized cells are collected from peripheral blood
    Subsequent useThe collected cells are used for subsequent autologous transplantation

    Initial Therapy

    Hematopoietic Stem Cell Mobilization

    Authorization of 6 months may be granted when both criteria are met.

    Initial hematopoietic stem cell mobilization

    • Allowed administration scenario

      • After G-CSF: The member has received a G-CSF, such as filgrastim.
      • After chemo-mobilization: The member has received chemo-mobilization.
      • Gene therapy protocol: The requested medication will be administered as part of a gene therapy protocol.

    Continuation of Therapy

    Continuation of Therapy

    All members, including new members and members currently receiving treatment without prior authorization, must meet all requirements in section B.

    Continuation therapy requirements

    • Administration scenario

      • After G-CSF: The member has received a G-CSF, such as filgrastim.
      • After chemo-mobilization: The member has received chemo-mobilization.
      • Gene therapy protocol: The requested medication is being used as part of a gene therapy protocol.

    Step Therapy Requirement

    StepRequirementQualifying failure criteria
    1Members must try and fail an A-rated generic equivalent before receiving brand medication.The generic medication must have failed because of an intolerable adverse event that was not an expected adverse event attributable to the active ingredient, and the event must be documented in the member’s chart.

    Quantity and Duration Limits

    Mozobil (plerixafor)
    MedicationMozobil (plerixafor)
    Maximum courseNo more than 4 consecutive days
    Use after harvest/apheresisNo use after completion of stem cell harvest/apheresis
    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyMozobil (plerixafor) Coverage
    Policy CodePolicy 03-2026
    Change TypeNo material change
    Effective DateJun 26, 2026
    Last ReviewMar 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for Mozobil (plerixafor) using the HMSA medical specialty drug policy fax form.
    SourceLink
    On This Page
    Coverage CriteriaTreatment LimitsProvider Requirements and Denial RisksClinical BackgroundKey DefinitionInitial TherapyContinuation of TherapyStep Therapy RequirementQuantity and Duration Limits
    The requested medication will not be used beyond 4 consecutive days or after completion of stem cell harvest/apheresis.
    4 consecutive days maximum and no use after completion of harvest/apheresis
    Documentation Required

    Document Generic Intolerance

    For a brand request based on generic failure, document the adverse event in the member’s chart and submit supporting evidence with the authorization request.

    • Specific, detailed chart documentation must include the adverse event description, date/time, severity, generic dosage and treatment duration, required intervention, and relevant tests or laboratory data, if any.
    • Alternatively, submit a MedWatch form documenting the generic trial, failure, and adverse reaction.
    Denial Risk

    Failure to Meet Criteria or Duration Limits

    Coverage may be denied when the request does not meet the applicable indication and authorization criteria or exceeds the policy’s use limitations. Authorization for hematopoietic stem cell mobilization is limited to 6 months, and the medication must not be used beyond 4 consecutive days or after completion of stem cell harvest/apheresis.

    • The medication must be administered after G-CSF, after chemo-mobilization, or as part of a gene therapy protocol.
    • All approval criteria must be met, including continuation requirements for members currently receiving treatment without prior authorization.
    • Dosing limits may apply under FDA-approved labeling, accepted compendia, or evidence-based practice guidelines; exclusions in the member’s benefit contract may also apply.
    Denial Risk

    Brand Request Without Qualifying Generic Failure

    A brand request is at risk of denial when the record does not establish a qualifying generic failure. The member must have failed the A-rated generic because of an intolerable adverse event that is not an expected reaction to the shared active ingredient and must have supporting documentation.

    • Failure to try the A-rated generic, failure to document the adverse event, or an adverse event expected for both brand and generic does not satisfy the brand-coverage requirement.
    • A stated difference in FDA-labeled indications, without a qualifying generic failure, is not sufficient justification for brand access.
    Treatment duration limit: The medication will not be used beyond 4 consecutive days or after completion of stem cell harvest/apheresis.4 consecutive days maximum and no use after completion of harvest/apheresis
    Treatment duration limit: The requested medication will not be used beyond 4 consecutive days or after completion of stem cell harvest/apheresis.4 consecutive days maximum and no use after completion of harvest/apheresis